ALDEYRA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.77 USD | -4.31% |
|
-9.38% | +7.41% |
Presenter SpeechTodd Brady (Executives)Welcome, everybody. I'm Todd Brady. I'm the President a...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Calendar
2024-06-03
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.77
USD
Average target price
9.25
USD
Spread / Average Target
+145.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.41% | 224M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ALDX Stock
- News Aldeyra Therapeutics, Inc.
- Transcript : Aldeyra Therapeutics, Inc. - Special Call
